{"authors": [["Morimoto", "M", "M", "Japanese Red Cross Tokushima Hinomine Rehabilitation Center for People with Disabilities, Tokushima, Japan."], ["Shimakawa", "S", "S", "Japanese Red Cross Tokushima Hinomine Rehabilitation Center for People with Disabilities, Tokushima, Japan."], ["Hashimoto", "T", "T", "Japanese Red Cross Tokushima Hinomine Rehabilitation Center for People with Disabilities, Tokushima, Japan."], ["Kitaoka", "T", "T", "Graduate School of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan."], ["Kyotani", "S", "S", "Graduate School of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan."]], "date": "2017-12-18", "id": "29265387", "text": "Dravet syndrome (DS) is an intractable epilepsy syndrome. The three-drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide.We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective.It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy.", "doi": "10.1111/jcpt.12659", "title": "Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.", "journal": ["Journal of clinical pharmacy and therapeutics", "J Clin Pharm Ther"]}